GSK1325760Aの評価に関する研究 - 長期延長試験

基本情報

NCT ID

NCT00554619

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

21

治験依頼者名

GlaxoSmithKline

概要

The primary objective of this study is to evaluate the safety of long-term administration of GSK1325760A in patients with PAH. The secondary objectives of this study are to evaluate long-term administration of GSK1325760A on: * Improvement in exercise capacity (six-minutes walk distance: 6MWD), change in WHO Functional Classification and time to clinical worsening of PAH * Change in the Borg Dyspnea Index (assessed immediately following the six-minute walk test \[6MWT\]) * Change in plasma brain natriuretic peptide (BNP) levels * Cardiopulmonary hemodynamics parameters (as measured by echocardiography)

対象疾患

介入

依頼者（Sponsor）